Related references
Note: Only part of the references are listed.Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients
Fred S. Sarfo et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Dependence of Efavirenz- and Rifampicin-Isoniazid-Based Antituberculosis Treatment Drug-Drug Interaction on CYP2B6 and NAT2 Genetic Polymorphisms: ANRS 12154 Study in Cambodia
Julie Bertrand et al.
JOURNAL OF INFECTIOUS DISEASES (2014)
Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial
Rebekah L. Puls et al.
LANCET (2014)
Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype
Helen M. McIlleron et al.
AIDS (2013)
A Pharmacokinetic Standard for Babies and Adults
Nick Holford et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2013)
Importance of Ethnicity, CYP2B6 and ABCB1 Genotype for Efavirenz Pharmacokinetics and Treatment Outcomes: A Parallel-Group Prospective Cohort Study in Two Sub-Saharan Africa Populations
Eliford Ngaimisi et al.
PLOS ONE (2013)
High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients
Marelize Swart et al.
PHARMACOGENETICS AND GENOMICS (2013)
Correlates of Efavirenz Exposure in Chilean Patients Affected With Human Immunodeficiency Virus Reveals a Novel Association With a Polymorphism in the Constitutive Androstane Receptor
Claudia P. Cortes et al.
THERAPEUTIC DRUG MONITORING (2013)
PXR and CAR single nucleotide polymorphisms influence plasma efavirenz levels in South African HIV/AIDS patients
Marelize Swart et al.
BMC MEDICAL GENETICS (2012)
Influence of CYP2B6 516G>T polymorphism and interoccasion variability (IOV) on the population pharmacokinetics of efavirenz in HIV-infected South African children
M. Viljoen et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2012)
CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans
Milimo Maimbo et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Mid-Dosing Interval Efavirenz Plasma Concentrations in HIV-1-Infected Children in Rwanda: Treatment Efficacy, Tolerability, Adherence, and the Influence of CYP2B6 Polymorphisms
Philippe R. Mutwa et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2012)
Multiple genetic variants predict steady-state nevirapine clearance in HIV-infected Cambodians
Julie Bertranda et al.
PHARMACOGENETICS AND GENOMICS (2012)
Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants
Emily R. Holzinger et al.
PHARMACOGENETICS AND GENOMICS (2012)
ABCB1 4036A>G and 1236C>T Polymorphisms Affect Plasma Efavirenz Levels in South African HIV/AIDS Patients
Marelize Swart et al.
Frontiers in Genetics (2012)
Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens
Christoph Wyen et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2011)
Long-Term Efavirenz Autoinduction and Its Effect on Plasma Exposure in HIV Patients
E. Ngaimisi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Tribal ethnicity and CYP2B6 genetics in Ugandan and Zimbabwean populations in the UK: implications for efavirenz dosing in HIV infection
Y. Jamshidi et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
Effect of CYP2B6, ABCB1, and CYP3A5 Polymorphisms on Efavirenz Pharmacokinetics and Treatment Response: An AIDS Clinical Trials Group Study
Heather J. Ribaudo et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
Presence of the CYP2B6 516G > T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients
Verena Gounden et al.
AIDS RESEARCH AND THERAPY (2010)
CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients
Awewura Kwara et al.
AIDS (2009)
A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans
Jackson K. Mukonzo et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Effect of Rifampicin on Efavirenz Pharmacokinetics in HIV-Infected Children With Tuberculosis
Yuan Ren et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2009)
In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function
Julia di Iulio et al.
PHARMACOGENETICS AND GENOMICS (2009)
Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients
Christoph Wyen et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
High prevalence of the CYP2B6 516G→T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe
Christopher Nyakutira et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Partial deletion of CYP2B6 owing to unequal crossover with CYP2B7
Margalida Rotger et al.
PHARMACOGENETICS AND GENOMICS (2007)
PLINK: A tool set for whole-genome association and population-based linkage analyses
Shaun Purcell et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2007)
High prevalence of subtherapeutic plasma concentrations of efavirenz in children
Yuan Ren et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2007)
Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals
M. Rotger et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir:: An adult AIDS clinical trials group study
DW Haas et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals
LM Almond et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2005)
Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects
S Rodriguez-Novoa et al.
CLINICAL INFECTIOUS DISEASES (2005)
Haploview: analysis and visualization of LD and haplotype maps
JC Barrett et al.
BIOINFORMATICS (2005)
A multi-investigator/institutional DNA bank for AIDS-related human genetic studies: AACTG Protocol A5128
DW Haas et al.
HIV CLINICAL TRIALS (2003)
The cytochrome P4502B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: Implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity
BA Ward et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS clinical trial group study 398
M Pfister et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Hepatic CYP2B6 expression: Gender and ethnic differences and relationship to CYP2B6 genotype and CAR (Constitutive Androstane Receptor) expression
V Lamba et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
Share Paper
